Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAV in Peripheral Arterial Disease
NCT01872208Phase 2Completed
- Sponsor
- Humacyte
- Start
- Oct 2013
- Primary completion
- May 2016
- Modality
- Device-based Delivery, Tissue Cells, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acellular tissue engineered vessel in Peripheral Arterial Disease (PAD), sponsored by Humacyte. Primary endpoints: Change in HAV characteristics, Change in HAV patency rate and 2 more. Started Oct 2013; status: completed.
02
Drugs
acellular tissue engineered vessel
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT01872208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01872208.